The Future of Early-Stage Deep Tech Investments in Europe
Join the conversation with Alexander Schwartz and Ingrid Kelly Spillmann
2006 was a fantastic year. The colossal crisis that hit the western world as the dot.com bubble burst was long forgotten, and capital seemed to be available at every corner. Nobody was aware yet of the coming doomsday of the global financial sector in 2008.
Many new companies started to take off in the first decade of the new millennium in life science.
Intercell- founded in 1998 - did its IPO on the Austrian stock market in 2005. Werner Lanthaler led the IPO as a CFO and built Evotec into a global innovation engine.
Marinomed started in 2006 as a spin-out of the University of Veterinary Medicine, founded by Andreas Grassauer and Eva-Maria Grassauer.
Nabriva - founded by Rodger Novak, now Co-Founder and President of CRISPR Therapeutics - was spun out of Novartis in 2006
Themis Bioscience started in 2009, led by Erich Tauber and acquired by MSD for 1,1 billion dollars (according to Pitchbook)
Apeiron Biologics started in 2003, developing the research results of Josef Penninger.
Keep reading with a 7-day free trial
Subscribe to Beginner’s Mind Podcast Notes by Christian Soschner to keep reading this post and get 7 days of free access to the full post archives.